Novel clinical evidence in continuous glucose monitoring

How do real-world CGM studies complement randomized controlled trials?

Jean-Pierre Riveline uses data from real-life continuous glucose monitoring studies to illustrate how these can uncover critical information about clinical outcomes that are hard to assess in randomized controlled trials.

Speaker

• Jean-Pierre Riveline
  Lariboisière Hospital in Paris, France. Read more

Speaker disclosure

• Advisory panel member for: Sanofi, MSD, Eli Lilly, Novo Nordisk, AstraZeneca, Abbott, Dexcom, Alphadiab, Insulet and Medtronic.
• Research funding and research support: Abbott, Insulet, Medtronic, Air Liquide, Sanofi, Roche and Novo Nordisk.

Financial disclosure

This video has been developed through unrestricted educational funding from Abbott Diabetes Care.

Disclaimer

Any information provided and opinions expressed do not necessarily reflect the views of Springer Medizin GmbH. Springer Medizin GmbH and its employees, agents and subcontractors are not responsible or in any way liable for the currency of the information, for any errors, omissions or inaccuracies, or for any consequences arising therefrom. Inclusion or exclusion of any product does not imply its use is either advocated or rejected. Use of trade names is for product identification only and does not imply endorsement. Please consult the latest prescribing information from the manufacturer before issuing prescriptions for any products mentioned.